Medicenna Therapeutics Analyst Ratings
Medicenna Therapeutics Analyst Ratings
While ratings are subjective and will change, the latest Medicenna Therapeutics (MDNA) rating was a reiterated with a price target of $0.00 to $2.50. The current price Medicenna Therapeutics (MDNA) is trading at is $0.41, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/10/2023 | 515.35% | HC Wainwright & Co. | → $2.5 | Reiterates | Buy → Buy |
| 07/31/2023 | 515.35% | HC Wainwright & Co. | → $2.5 | Reiterates | Buy → Buy |
| 06/28/2023 | 515.35% | HC Wainwright & Co. | → $2.5 | Reiterates | Buy → Buy |
| 02/08/2023 | 515.35% | HC Wainwright & Co. | → $2.5 | Reiterates | → Buy |
| 11/08/2022 | 515.35% | HC Wainwright & Co. | $4 → $2.5 | Maintains | Buy |
| 08/16/2022 | 884.56% | HC Wainwright & Co. | $5 → $4 | Maintains | Buy |
| 06/23/2022 | 2361.41% | Oppenheimer | $12 → $10 | Maintains | Outperform |
| 06/23/2022 | 1130.7% | HC Wainwright & Co. | $7 → $5 | Maintains | Buy |
| 06/01/2021 | 1622.98% | HC Wainwright & Co. | $8 → $7 | Maintains | Buy |
| 12/18/2020 | 2853.69% | Oppenheimer | → $12 | Initiates Coverage On | → Outperform |
| 12/17/2020 | 2853.69% | Oppenheimer | → $12 | Initiates Coverage On | → Outperform |
| 09/10/2020 | 1869.12% | HC Wainwright & Co. | → $8 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月10日 | 515.35% | HC Wainwright公司 | →$2.5 | 重申 | 購買→購買 |
| 07/31/2023 | 515.35% | HC Wainwright公司 | →$2.5 | 重申 | 購買→購買 |
| 2023年6月28日 | 515.35% | HC Wainwright公司 | →$2.5 | 重申 | 購買→購買 |
| 02/08/2023 | 515.35% | HC Wainwright公司 | →$2.5 | 重申 | →購買 |
| 11/08/2022 | 515.35% | HC Wainwright公司 | $4→$2.5 | 維護 | 買 |
| 08/16/2022 | 884.56% | HC Wainwright公司 | $5→$4 | 維護 | 買 |
| 2022/06/23 | 2361.41% | 奧本海默 | $12→$10 | 維護 | 跑贏大盤 |
| 2022/06/23 | 1130.7% | HC Wainwright公司 | $7→$5 | 維護 | 買 |
| 06/01/2021 | 1622.98% | HC Wainwright公司 | $8→$7 | 維護 | 買 |
| 12/18/2020 | 2853.69% | 奧本海默 | →$12 | 開始承保 | →跑贏大盤 |
| 12/17/2020 | 2853.69% | 奧本海默 | →$12 | 開始承保 | →跑贏大盤 |
| 09/10/2020 | 1869.12% | HC Wainwright公司 | →$8 | 開始承保 | →購買 |
What is the target price for Medicenna Therapeutics (MDNA)?
Medicenna Treeutics(MDNA)的目標價格是多少？
The latest price target for Medicenna Therapeutics (NASDAQ: MDNA) was reported by HC Wainwright & Co. on August 10, 2023. The analyst firm set a price target for $2.50 expecting MDNA to rise to within 12 months (a possible 515.35% upside). 6 analyst firms have reported ratings in the last year.
2023年8月10日，HC Wainwright&Co.報道了Medicenna治療公司(納斯達克：mDNA)的最新目標價。這家分析公司將目標價定為2.5美元，預計mDNA將在12個月內上漲至(可能上漲515.35%)。6家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for Medicenna Therapeutics (MDNA)?
Medicenna治療公司(MDNA)的最新分析師評級是多少？
The latest analyst rating for Medicenna Therapeutics (NASDAQ: MDNA) was provided by HC Wainwright & Co., and Medicenna Therapeutics reiterated their buy rating.
美第奇拿治療公司(納斯達克代碼：mDNA)的最新分析師評級由HC Wainwright&Co.提供，美第奇拿治療公司重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Medicenna Therapeutics (MDNA)?
Medicenna治療公司(MDNA)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Medicenna Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Medicenna Therapeutics was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Medicenna Treeutics的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Medicenna治療公司的上一次評級是在2023年8月10日提交的，所以你應該預計下一次評級將在2024年8月10日左右的某個時候提供。
Is the Analyst Rating Medicenna Therapeutics (MDNA) correct?
分析師對Medicenna Treeutics(MDNA)的評級正確嗎？
While ratings are subjective and will change, the latest Medicenna Therapeutics (MDNA) rating was a reiterated with a price target of $0.00 to $2.50. The current price Medicenna Therapeutics (MDNA) is trading at is $0.41, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Medicenna治療(MDNA)評級被重申，目標價在0.00美元至2.50美元之間。Medicenna Treateutics(MDNA)目前的交易價格為0.41美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。
